Although still in nascent stages, AI-derived therapeutics such as glucagon-like peptide 1 receptor (GLP1R) for type 2 diabetes and obesity, apelin receptor (APLNR) for pulmonary arterial hypertension and idiopathic pulmonary fibrosis, Rho-associated coiled-coil-containing protein kinase 1/2 (ROCK1/2) for diabetic complications, and sphingosine-1-phosphate 1 (S1P1) for postmyocardial infarction care are making headway in clinical research (31). Here, GLP1R is linked to obesity disorder.